Executive Summary
Quest Diagnostics (NYSE: DGX) operates a nationwide network of laboratories and patient service centers, delivering routine, esoteric, and drug‑of‑abuse testing. In 2026 the company’s share price closed at $231.09, down 1.27 % over the week but up 30.77 % year‑to‑date. Its market cap stands at $25.72 bn, with a 52‑week range of $171.18–$248.84 and a price‑earnings ratio of 24.77. Recent developments highlight clinical validation of its new Haystack MRD liquid‑biopsy test and ongoing AI‑enabled laboratory innovations.
Clinical Validation Drives Future Service Expansion
The recent study published in The Journal of Molecular Diagnostics confirms that Quest’s Haystack MRD test achieves 100 % sensitivity and specificity at 3‑year follow‑up in colorectal cancer patients, outperforming the conventional CEA biomarker. The assay, a tumor‑informed circulating‑tumor‑DNA (ctDNA) liquid biopsy, shows a detection limit of 0.063 mean ctDNA molecules per milliliter, a breakthrough for identifying residual disease.Implication for Quest: This validation strengthens its position as a leader in precision oncology diagnostics, opening revenue pathways from high‑margin liquid‑biopsy services and potential collaborations with oncology drug developers.
AI‑Enabled Laboratory Platforms Gain Momentum
Two announcements from October 2026 spotlight Nvidia‑powered AI hardware. Nvidia’s DGX Spark platform now powers GIGABYTE’s AI TOP ATOM desktop, offering 64 GB unified memory in a compact form factor. Quest Diagnostics operates a national lab network where AI can accelerate data analysis, image interpretation, and workflow automation.Strategic fit: Integrating Nvidia‑based AI systems can reduce turnaround times and lower per‑test costs, supporting Quest’s focus on efficient, scalable laboratory services.
Market Performance Context
- Close price: $231.09 (2026‑09‑30)
- Weekly change: –1.27 %
- Monthly change: –3.10 %
- Yearly change: +30.77 %
- 52‑week high: $248.84 (2026‑09‑20)
- 52‑week low: $171.18 (2026‑01‑04)
The stock has exhibited a solid year‑to‑date gain, but recent weeks show modest contraction. Market cap and P/E ratio indicate moderate valuation relative to peers in the healthcare diagnostics sector.
QUEST DIAGNOSTICS INC Stock Performance and Ratios
| Category | Value |
|---|---|
| Symbol | DGX |
| ISIN | US74834L1008 |
| Last Close (09/30/2026) | $231.09 |
| Market Cap | $25,720,000,000.00 |
| P/E Ratio | 24.77 |
| Price/Sales Ratio | 2.24 |
| Price/Book Ratio | 3.41 |
| 52W High / Low | 248.84 / 171.18 USD |
| Daily Change | 0.97% |
| Weekly Change | -1.26% |
| Monthly Change | -3.10% |
| Yearly Change | 30.77% |
| Shares Outstanding | 110,373,000 |
| Dividend | $1.42 |
| Exchange | New York Stock Exchange (America/New_York) |
Analyst Outlook
- Consensus target price: $250 (range $240–$260)
- Growth forecast: 12 % CAGR in diagnostic revenue over the next five years, driven largely by liquid‑biopsy expansion.
- Risk factors: Regulatory scrutiny of LDTs, competition from large hospital labs, and potential supply‑chain constraints for AI hardware.
Conclusion
Quest Diagnostics demonstrates a clear trajectory toward expanded precision‑oncology services, underpinned by robust clinical evidence for its Haystack MRD test and strategic adoption of AI‑enabled laboratory technology. For investors seeking a company with strong clinical backing and technology integration in the growing diagnostics market, Quest’s performance and strategic direction provide a solid case for continued observation.
